Accessibility Menu
Lantern Pharma logo

Lantern Pharma(NASDAQ) LTRN

Current Price$2.99
Market Cap$36.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-80%
5 Year-79%
1 Year-30%
1 Month-27%
Lantern Pharma last closing stock price
MetricPriceDate
Last closeUSD 2.842026-07-22
Lantern Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.39%USD 3.102026-07-15
1 month-26.8%USD 3.882026-06-22
3 month+22.94%USD 2.312026-04-23
Year to date-6.27%USD 3.032025-12-31
1 year-29.53%USD 4.032025-07-22
3 year-37.72%USD 4.562023-07-21
5 year-79.38%USD 13.772021-07-23
Since inception-80.33%USD 14.952020-06-11

Lantern Pharma Financials at a Glance

Market Cap

$36.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$15.91M

EPS (TTM)

-$1.45

P/E Ratio

-1.97

Dividend

$0.00

Beta (Volatility)

1.41 (Average)

Price

$2.99

Volume

433

Open

$2.93

Previous Close

$2.99

Daily Range

$2.91 - $3.05

52-Week Range

$1.11 - $5.74

Estimated Earnings Date

Aug 12, 2026

LTRN News

Foolcom-Featured.png

Lantern Pharma Narrows Loss in Q2

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lantern Pharma

Lantern Pharma develops cancer drugs using artificial intelligence and genetic data. Its main products aim to help patients with hard-to-treat cancers. The company’s technology matches treatments to people most likely to benefit.

What’s in the Lantern Toolbox?

  • LP-300 (Tavocept): Drug in Phase 2 trials for non-smokers with advanced lung cancer; no revenue contribution yet.
  • LP-184: Drug in Phase 1 trials for several solid tumors and brain cancers; no revenue contribution yet.
  • LP-284: Drug in Phase 1 trials for blood cancers; no revenue contribution yet.
  • LP-100: Drug previously in Phase 2 for advanced prostate cancer; no revenue contribution yet.
  • ADC Program: Early-stage research on antibody-drug conjugates, which link antibodies to cancer-killing drugs; no revenue contribution yet.
  • RADR Platform: Artificial intelligence system that analyzes large data sets to find new drug candidates and match them to patient groups; no revenue contribution yet.

Lantern’s Growth Spurt: The Highlights

  • Formed Starlight Therapeutics in 2023 to develop brain cancer drugs.
  • Expanded the RADR platform to over 200 billion data points by 2025.
  • Partnered with Bielefeld University in 2023 for antibody-drug conjugate research.
  • Signed an equity sales agreement with ThinkEquity in July 2025 for up to $15.53 million in funding.
  • Operates in the US, UK, and Australia, focusing on clinical trials and research partnerships.

Lantern’s Secret Sauce

Lantern uses artificial intelligence to speed up drug discovery and target specific patient groups. Its approach focuses on reviving older drug candidates with new data insights. The company relies on partnerships and external research to expand its pipeline.

Five Things You Need to Know

  • No revenue reported for Q2 2025, Q2 2024, or Q2 2023.
  • Net loss was $4.5 million in Q2 2025, up 90.3% from Q2 2024.
  • Cash and marketable securities were $34 million in Q2 2025, down 29.9% from Q2 2024.
  • Research and development expenses were $3.07 million in Q2 2025.

Bottom Line

Lantern focuses on AI-driven cancer drug development with no product sales yet. The company’s future depends on clinical progress and continued funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

16

CEO

Panna L. Sharma

Website

www.lanternpharma.com

Headquarters

Dallas, TX 75201, US

LTRN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-198.35%

Return on Capital

-21.13%

Return on Assets

-220.29%

Earnings Yield

-50.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$36.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.76M

Volume

433

Avg. Volume

235.25K

Financials (TTM)

Gross Profit

-$3.85K

Operating Income

-$16.61M

EBITDA

-$15.90M

Operating Cash Flow

-$15.07M

Capital Expenditure

-$567.00

Free Cash Flow

-$15.07M

Cash & ST Invst.

$6.32M

Total Debt

$59.08K

Lantern Pharma Performance Analysis

Lantern Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Lantern Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Lantern Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.3115.9%
20232023-12-31USD -1.4712.0%
20242024-12-31USD -1.9331.2%
20252025-12-31USD -1.57-18.6%
Lantern Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.8%
Q32025-09-302.5%
Q42025-12-317.7%
Q12026-03-3116.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$3.85K

N/A

Gross Margin

0.00%

N/A

Market Cap

$36.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.26M

N/A

Employees

16

N/A

Net Income

-$3.33M

+26.6%

EBITDA

-$3.33M

+26.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.32M

-67.9%

Total Debt

$59.08K

-69.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$59.08K

-63.4%

Return on Assets

-2.20%

N/A

Return on Invested Capital

-4.82%

N/A

Free Cash Flow

-$3.77M

+13.8%

Operating Cash Flow

-$3.77M

+13.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANVSAnnovis Bio, Inc.
$1.74-0.57%
RNXTRenovoRx, Inc.
$0.87-1.38%
ELUTElutia Inc
$0.93-1.89%
LVTXLAVA Therapeutics N.V.
$1.74-3.87%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$212.25+0.02%
NOKNokia
$10.28-0.03%
SPCXSpace Exploration Technologies
$115.31-0.07%
NUNu Holdings
$14.50+0.01%

Questions About LTRN

What is the current price of Lantern Pharma?

Lantern Pharma is trading at $2.99 per share.

What is the 52-week range for Lantern Pharma?

Over the past 52 weeks, Lantern Pharma has traded between $1.11 and $5.74.

How much debt does Lantern Pharma have?

As of the most recent reporting period, Lantern Pharma reported total debt of $59.08K.

How much cash does Lantern Pharma have on hand?

Lantern Pharma reported $4.92M in cash and cash equivalents in its most recent financial results.

What is Lantern Pharma’s dividend yield?

Lantern Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services